Market Trends of Post Operative Pain Management Industry
Non-steroidal anti-inflammatory drugs (NSAIDs) Segment is Expected to Hold a Significant Share in the Postoperative Pain Management Market
The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to hold a significant market share by drug class. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to relieve pain, reduce inflammation, and bring down high body temperatures. The major factors fueling the segment's growth are the implementation of strategic initiatives by the market players, the growing demand for NSAIDs owing to their advantages over other drugs, and the increasing number of surgical procedures. For instance, in July 2021, Hyloris Pharmaceuticals SA, a specialty biopharmaceutical company committed to addressing unmet medical needs through the reinvention of existing medications, reported that Maxigesic IV would be available in Germany and Austria. Maxigesic IV is a novel, patented, non-steroidal anti-inflammatory drug that is a unique combination of 1000 mg of paracetamol and 300 mg of ibuprofen solution for infusion. Hyloris' partner company, AFT Pharmaceuticals, works with distribution partners with a strong local presence to commercialize the product worldwide.
Moreover, a June 2021 published study titled Adult outpatients reported better pain scores and fewer adverse effects when their postoperative pain was treated with NSAIDs than codeine. Such studies indicating the efficacy of NSAIDs in postoperative pain management contribute to the segment's growth. Additionally, product launches by the market players are expected to propel the market's growth. For instance, in December 2021, Heron Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to significantly expand the indication.
Thus, the segment is expected to grow significantly over the forecast period due to the abovementioned factors.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The United States is expected to hold a significant share of the market in North America. The major factors bolstering the market's growth are the growing number of surgical procedures, the surge in awareness regarding postoperative pain management drugs, the increasing number of product approvals, and the rising focus on palliative care.
The increase in the number of surgeries in the country is expected to propel the growth of the market. For instance, the Personalised Orthopaedics of the Palm Beaches statistics published in November 2021 show that almost 800,000 knee replacements are performed each year in the United States, and the number is estimated to increase year on year. Additionally, Cedars-Sinai data updated in January 2022 shows that coronary artery bypass graft surgery (CABG), also known as coronary artery bypass or bypass surgery, is the most common type of heart surgery. More than 300,000 people have successful bypass surgery in the United States each year. Such statistics are likely to increase the demand for postoperative pain management medications within the country, thereby boosting the market's growth.
In addition, several market players are engaged in implementing strategic initiatives, thereby contributing to the market's growth. For instance, in May 2021, Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform postsurgical pain management and recovery, reported the first-ever clinical data showing non-opioid pain relief lasting two weeks after a single administration.
Moreover, an increasing number of product approvals is also expected to contribute to the market's growth. For instance, in May 2021, The FDA has approved a Heron Therapeutics combination medicine designed to manage postoperative pain and assist patients avoid the use of narcotic painkillers, a regulatory decision that comes after the agency previously rejected the biotech's applications. The Heron medication, which combines bupivacaine and meloxicam, is approved to treat postsurgical pain for up to 72 hours after three procedures: bunionectomy, open surgery hernia repair, and total knee replacement.
Thus, owing to the abovementioned factors, the market is expected to witness significant growth over the forecast period.
